Pharmacodynamic study of the 7,8-dihydroxy-4-methylcoumarininduced selective cytotoxicity toward U-937 leukemic cells versus mature monocytes: Cytoplasmic p21Cip1/WAF1 as resistance factor

Biochemical Pharmacology

Volumn 86, Issue 2, 2013, Pages 210-221

  Vazquez, Ramiro ^a,b   Riveiro, Maria Eugenia ^a   Mondillo, Carolina ^a   Perazzo, Juan Carlos ^b   Vermeulen, Monica ^c   Baldi, Alberto ^a   Davio, Carlos ^b   Shayo, Carina ^a,b  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

Apoptosis; DHMC; Leukemia; P21Cip1 WAF1; Selective cytotoxicity; Sub acute toxicity

Indexed keywords

7,8 DIHYDROXY 4 METHYLCOUMARIN; COUMARIN DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ZINC CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER THERAPY; CELL DIFFERENTIATION; CELL TRANSFER; CONTROLLED STUDY; DRUG CYTOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MALE; MONOCYTE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; R FACTOR;

EID: 84884900538     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.04.021     Document Type: Article

References (34)

1. Riveiro ME, Shayo C, Monczor F, Fernandez N, Baldi A, De Kimpe N, et al. Induction of cell differentiation in human leukemia U-937 cells by 5-oxygenated- 6,7-methylenedioxycoumarins from Pterocaulon polystachyum. Cancer Lett 2004;210:179-88. (Pubitemid 38748688)
2. Riveiro ME, Moglioni A, Vazquez R, Gomez N, Facorro G, Piehl L, et al. Structural insights into hydroxycoumarin-induced apoptosis in U-937 cells. Bioorg Med Chem 2008;16:2665-75. (Pubitemid 351380918)
3. Riveiro ME, Vazquez R, Moglioni A, Gomez N, Baldi A, Davio C, et al. Biochemical mechanisms underlying the pro-apoptotic activity of 7,8-dihydroxy-4- methylcoumarin in human leukemic cells. Biochem Pharmacol 2008;75: 725-36.
4. Riveiro ME, Maes D, Vazquez R, Vermeulen M, Mangelinckx S, Jacobs J, et al. Toward establishing structure-activity relationships for oxygenated coumarins as differentiation inducers of promonocytic leukemic cells. Bioorg Med Chem 2009;17:6547-59.
5. Vazquez R, Riveiro ME, Vermeulen M, Mondillo C, Coombes PH, Crouch NR, et al. Toddaculin, a natural coumarin from Toddalia asiatica, induces differentiation and apoptosis in U-937 leukemic cells. Phytomedicine 2012;19: 737-46.
6. Vazquez R, Riveiro ME, Vermeulen M, Alonso E, Mondillo C, Facorro G, et al. Structure-anti-leukemic activity study of ortho-dihydroxycoumarins in U-937 cells: key role of the - lactone ring in determining differentiation-inducing potency and pro-apoptotic action. Bioorg Med Chem 2012;20:5537-49.
7. Goel A, Prasad AK, Parmar VS, Ghosh B, Saini N. 7,8-Dihydroxy-4- methylcoumarin induces apoptosis of human lung adenocarcinoma cells by ROS-independent mitochondrial pathway through partial inhibition of ERK/MAPK signaling. FEBS Lett 2007;581:2447-54. (Pubitemid 46764704)
8. Abdel-Wahab O, Levine RL. Metabolism and the leukemic stem cell. J Exp Med 2010;207:667-80.
9. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, et al. Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation. EMBO J 1999;18:1223-34. (Pubitemid 29110307)
10. Abbas T, Dutta A. p21 in cancer: intrincate networks and multiple activities. Nat Rev Cancer 2009;9:400-14.
11. Romanov VS, Pospelov VA, Pospelova TV. Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenic. Biochemistry 2012;77:575-84.
12. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL. Cytoplasmic p21WAF1/Cip1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 2003;5:242-9.
13. Ferrandiz N, Caraballo JM, Albajar M, Gomez-Casares MT, Lopez-Jorge CE, Blanco R, et al. P21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells. Cancer Lett 2010;292:133-9.
14. Koster R, di PietroA, Timmer-Bosscha H, Gibcus JH, van der Berg A, Suurmeijer AJ, et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 2010;120:3594-605.
15. Koster R, de Jong S. Lessons learned from testicular cancer: identification of cytoplasmic p21 as Achille's heel of cisplatin resistance. Cell Cycle 2010;9:4776-7.
16. Xia X, Ma Q, Li X, Ji T, Chen P, Xu H, et al. Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer 2011;11:399-408.
17. Rommer A, Steinmetz B, Herbst F, Hackl H, Heffeter P, Heilos D, et al. EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells. PloS ONE 2013;8:e56308.
18. Chuluyan HE, Issekutz AC. VLA-4 integrin can mediate CD11/CD18- independent transendothelial migration of human monocytes. J Clin Invest 1993;92:2768-77. (Pubitemid 24006543)
19. Kew RR, Peng T, DiMartino SJ, Madhavan D, Weinman SJ, Cheng D, et al. Undifferentiated U937 cells transfected with chemoattractant receptors: a model system to investigate chemotactic mechanisms and receptor structure/ function relationships. J Leukoc Biol 1997;61:329-37. (Pubitemid 27149912)
20. Shim J, Lee H, Park J, Kim H, Choi EJ. A non-enzymatic p21 inhibitor of stressactivated protein kinases. Nature 1996;381:805-6.
21. Zhan J, Easton JB, Huang S, Mishra A, Xiao L, Lacy ER, et al. Negative regulation of ASK1 by p21Cip1 involves a small domain that includes Serine 98 that is phosphorylated by ASK1 in vivo. Mol Cell Biol 2007;27:3530-41. (Pubitemid 46685227)
22. Abraham K, Wo hrlin F, Lindtner O, heinemeyer G, Lampen A. Toxicology and risk assessment of coumarin: focus on human data. Mol Nutr Food Res 2010;54:228-39.
23. Borges F, Roleira F, Milhazes N, Santana L, Uriarte E. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr Med Chem 2005;12:887-916. (Pubitemid 40443846)
24. Riveiro ME, De Kimpe N, Moglioni A, Vazquez R, Monczor F, Shayo C, et al. Coumarins: old compounds with novel promising therapeutic perspectives. Curr Med Chem 2010;17:1325-38.
25. Kontogiorgis C, Detsi A, Hadjipavlou-Litina D. Coumarin-based drugs: a patent review (2008 - present). Expert Opin Ther Pat 2012;22:437-54.
26. Suzuki A, Tsutomi Y, Akahane K, Araki Miura M. Resistance to fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 1998;17:931-9. (Pubitemid 28425403)
27. Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K. Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ 2000;7:721-8. (Pubitemid 30599253)
28. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-49.
29. Shiizaki S, Naguro I, Ichijo H. Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling. Adv Biol Regul 2013;53:135-44.
30. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006;160:1-40. (Pubitemid 43227479)
31. Goel A, Prasad AK, Parmar VS, Ghosh B, Saini N. Apoptogenic effect of 7,8- diacetoxi-4-methylcoumarin and 7, 8-diacetoxy-4-methylthiocoumarin in human lung adenocarcinoma cell line: role of NK-kappaB, Akt, ROS and MAP kinase pathway. Chem Biol Interact 2009;179:363-74.
32. Ohta M. Present status and perspectives regarding the therapeutic strategy for acute myeloid leukemia, non-Hodgkin's lymphoma and multiple myeloma in elderly. Geriatr Gerontol Int 2009;9:115-23.
33. Alves-Rosa F, Vulcano M, Beigier-Bompadre M, Fernandez G, Palermo M, Isturiz MA. Interleukin-1a induces in vivo tolerance to lipopolysaccharide in mice. Clin Exp Immunol 2002;128:221-8. (Pubitemid 34534034)
34. Lacy A, O'Kennedy R. Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des 2004;10:3797-811. (Pubitemid 39409871)